A Review of Anti-HER2 Targeted Agents in Non-Breast Solid Tu

This review summarizes current utilization of anti-HER2 targeted therapy across several non-breast solid tumors in the setting of advanced disease.

Related Keywords

South Korea , Japan , University Of Washington , Washington , United States , Harwood , Seattle , American , Megan Alhadeff , Javlem Overexpression , Thanh Bui , Tiffany Tam , Chemother Pharmacol , Kanwal Pratap Singh Raghav , Salvatore Siena , Van Cutsem , Atsuo Takashima , Daiichi Sankyo , Fred Hutchinson Cancer Center , American Society For Clinical Pathology , American Society Of Clinical Oncology , Genentech , American Society Of Consultant Pharmacists , Zanidatamab Jazz Pharmaceuticals , Novartis , Pieris Pharmaceuticals , World Health Organization , Remegen Co , National Comprehensive Cancer Network , University Of Washington Medicine , College Of American Pathologists , American Society , Clinical Oncology , Consultant Pharmacists , American Pathologists , Esophagogastric Junction , Taiho Oncology , Janssen Biotech , Astellas Pharma , Jazz Pharmaceuticals , Clinical Pathology , Practice Guidelines , Gastric Cancer , Colon Cancer , Natl Compr Canc , Puma Biotechnology , Breast Cancer , Accessed December , Appl Immunohistochem Mol , Uterine Neoplasms , Pratap Singh Raghav , Targeted Agent , Profiling Utilization Registry , European Thoracic Oncology Platform , Cancer Treat , Dos Anjos , Case Rep , Jpnj Clin , Clin Cancer , Bladder Cancer , Washington Medicine ,